US$ 23.08
metsera glp-1 Pfizer's new prize touts 14.1% weight loss for Metsera Seeks $289M Raise, $1.78B
Description
Urva S, et al

Novo Nordisk also developed a combination drug product called IDegLira, a combination of the GLP-1 agonist liraglutide (Victoza) and the long-acting insulin degludec (Tresiba, Novo Nordisk)

30 The delivery device for dulaglutide does not require the patient to attach a needle and it may therefore be the preferred agent for those who have poor dexterity or are needle phobic

8c1c3)

However, these results did not reach Bonferroni-corrected significance [66]
